Stock Ticker

  • Loading stock data...

Merck (NYSE:MRK) Receives Approval for KEYTRUDA From the EMA As First-Line MSI-H/dMMR Colorectal Cancer Treatment

Merck (NYSE:MRK) has announced that the European Medicines Agency’s Committee for Medicinal Product for Human Use has adopted a positive view recommending KEYTRUDA approval. EMA’s CHMP approves KEYTRUDA as MSI-H/dMMR cancer treatment KEYTRUDA is the company’s anti-PD-1 therapy used as a monotherapy for first-line mismatch repair deficient (dMMR) or metastatic microsatellite instability-high (MSI-H) colorectal cancer […]

Merck (NYSE:MRK) Makes Investment In Seattle Genetics Inc. (NASDAQ:SGEN) For Development Of Ladiratuzumab Vedotin

Merck (NYSE:MRK) has entered a development agreement for Seattle Genetics Inc. (NASDAQ:SGEN) ladiratuzimab vedotin antibody-drug conjugate (ADC). Merck joins Gilead in investing in ADC-developer with a stake in Seattle Genetics The agreement came hours after Gilead Sciences Inc. (NYSE:GILD) announced the acquisition of Immunomedics for $21 billion. The centerpiece of Gilead’s deal is Immunomedic’s anti-Trop-2 […]